Skip to main content
. 2018 Jan 30;8:1840. doi: 10.1038/s41598-018-20325-0

Figure 4.

Figure 4

Graphical panel presenting the most relevant interactions involving the pembrolizumab heavy-chain residues. (a) Y33 and Y35; (b) R99, D100 and Y101; (c) R102 and (d) F103, M105 and D108, respectively.